2 stellar ASX 200 growth shares analysts rate as buys

Here are a couple of exciting growth shares that have been rated as buys…

| More on:
a happy investor with a wide smile points to a graph that shows an upward trending share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Looking for growth shares to buy? Listed below are two ASX 200 growth shares that have recently been named as buys.

Here's why they could be top options for growth investors next week:

Allkem Ltd (ASX: AKE)

The first ASX 200 growth share to consider is Allkem. It is one of the world's leading lithium miners with a collection of world class operations and projects.

Allkem appears well-placed for growth over the next few years thanks to its production growth plans and favourable lithium prices. In respect to the former, although Allkem is already a significant producer of lithium, it recently revealed plans to increase its production three-fold by 2026.

Management notes that this will allow the company to maintain a 10% share of the global lithium market over the next decade.

Morgans is bullish on the company and has an add rating and $16.98 price target on Allkem's shares. It commented:

AKE has been a strong performer in recent weeks but we continue to see long term valuation upside with persistent tightness in the lithium market.

We don't think spot prices are likely to remain at current levels forever but we think there is still plenty of scope for contract prices to increase further before settling down into a long term average.

Pro Medicus Limited (ASX: PME)

Another ASX 200 growth share that could be in the buy zone is Pro Medicus. It is an industry-leading provider of software that facilitates the clinical assessment of medical images.

This software has been in demand with healthcare institutions thanks to its ability to process, transfer and store medical images and associated data efficiently. And given that speed and accuracy is fundamentally linked to both treatment success and commercial incentives, it isn't hard to see why demand is strong and Pro Medicus keeps announcing huge long term contracts.

This has caught the eye of analysts at Bell Potter, which have put a buy rating and $55.00 price target on the company's shares. The broker commented:

Visage 7 is the fastest, most versatile viewing software on the market and it is the key reason why Pro Medicus has been successful in winning numerous high profile hospital contracts in the US, ahead of some of the largest global names in the industry.

Furthermore, although its shares trade on higher than average multiples, the broker believes that Pro Medicus' "prospective EPS growth is supportive of this large premium."

Motley Fool contributor James Mickleboro has positions in Allkem Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Pro Medicus Ltd. The Motley Fool Australia has positions in and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Growth Shares

3 unstoppable ASX shares to buy and hold for the next decade

These shares are going places over the remainder of the decade and beyond.

Read more »

Four piles of coins, each getting higher, with trees on them.
Growth Shares

2 high-growth ASX shares to buy today: brokers

These stocks have a strong growth outlook.

Read more »

Two university students in the library, one in a wheelchair, log in for the first time with the help of a lecturer.
Growth Shares

2 top-quality ASX shares to buy for beginner investors

These stocks could be a great place to start investing.

Read more »

A man in full American NFL playing kit crouches over with his arms across his chest in a defensive stance against a dark background.
Growth Shares

Here's why these two ASX 300 shares are great ones to own

These businesses are two of the fastest-growing stocks in the ASX 300 and are liked by fund manager WAM.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Growth Shares

3 ASX growth shares you'll wish you bought in June

Analysts think these shares could be destined for big things in the future.

Read more »

Father and daughter with hands on a small plant.
ETFs

Focused on growth? Here are 3 ASX ETFs to consider

Growth investors must ignore the current market noise about tariffs and focus on the long-term horizon.

Read more »

A female broker in a red jacket whispers in the ear of a man who has a surprised look on his face as she explains which two ASX 200 shares should do well in today's volatile climate
Growth Shares

Top brokers name 3 top ASX growth shares to buy now

Why are brokers feeling bullish on these names? Let's find out.

Read more »

Two plants grow in jars filled with coins.
Growth Shares

3 ASX 200 growth stocks up more than 100% in 1 year that could charge higher

It's been a memorable year for shareholders of these 3 companies.

Read more »